Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
287 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.
55% more call options, than puts
Call options by funds: $16.6M | Put options by funds: $10.7M
47% more repeat investments, than reductions
Existing positions increased: 115 | Existing positions reduced: 78
39% more first-time investments, than exits
New positions opened: 50 | Existing positions closed: 36
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
18% more capital invested
Capital invested by funds: $4.55B → $5.34B (+$797M)
5% more funds holding
Funds holding: 274 → 287 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$36.7M |
| 2 |
Holocene Advisors
New York
|
+$36.1M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$35.4M |
| 4 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
+$31.1M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$30.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$207M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$62M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$47.1M |
| 4 |
DM
Deerfield Management
New York
|
-$39.7M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$36.7M |
ITCI Hedge Fund Activity: Q2 2023 in Review
287 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.
Buyers outnumbered sellers: 50 funds opened new ITCI positions and 36 closed out — a net gain of 14 holders — while 115 added to existing stakes and 78 trimmed.
The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.
- 287 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
- Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
- 50 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +14 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
- The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.
Based on aggregated 13F filings for Q2 2023.